{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:54:30Z","timestamp":1784350470968,"version":"3.55.0"},"reference-count":175,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Tardive dyskinesia is a serious, disabling, movement disorder associated with the ongoing use of antipsychotic medication. Current evidence regarding the pathophysiology of tardive dyskinesia is mainly based on preclinical animal models and is still not completely understood. The leading preclinical hypothesis of tardive dyskinesia development includes dopaminergic imbalance in the direct and indirect pathways of the basal ganglia, cholinergic deficiency, serotonin receptor disturbances, neurotoxicity, oxidative stress, and changes in synaptic plasticity. Although, the role of the glutamatergic system has been confirmed in preclinical tardive dyskinesia models it seems to have been neglected in recent reviews. This review focuses on the role and interactions of glutamate receptors with dopamine, acetylcholine, and serotonin in the neuropathology of tardive dyskinesia development. Moreover, preclinical and clinical results of the differentiated effectiveness of <jats:italic toggle=\"yes\">N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate (NMDA) receptor antagonists are discussed with a special focus on antagonists that bind with the GluN2B subunit of NMDA receptors. This review also presents new combinations of drugs that are worth considering in the treatment of tardive dyskinesia.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000563","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T11:05:48Z","timestamp":1590577548000},"page":"511-523","source":"Crossref","is-referenced-by-count":20,"title":["The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: preclinical and clinical results"],"prefix":"10.1097","volume":"31","author":[{"given":"Anna Maria","family":"Szota","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Collegium Medicum in Bydgoszcz; Nicolaus Copernicus University in Toru\u0144; 9 Curie-Sk\u0142odowskiej Street, 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Scheel-Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Center of Functionally Integrative Neuroscience (CFIN), University of Aarhus, 8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"R1-20230910","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0091270009336735","article-title":"Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson\u2019s disease.","volume":"49","author":"Addy","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R2-20230910","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders.","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci"},{"key":"R3-20230910","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol Ther"},{"key":"R4-20230910","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-L","article-title":"Functional architecture of basal ganglia circuits: neural substrates of parallel processing.","volume":"13","author":"Alexander","year":"1990","journal-title":"Trends Neurosci"},{"key":"R5-20230910","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/mds.870040107","article-title":"Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia.","volume":"4","author":"Andersson","year":"1989","journal-title":"Mov Disord"},{"key":"R6-20230910","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0301-0082(99)00064-7","article-title":"Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?","volume":"61","author":"Andreassen","year":"2000","journal-title":"Prog Neurobiol"},{"key":"R7-20230910","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1476-5381.1996.tb15736.x","article-title":"Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats.","volume":"119","author":"Andreassen","year":"1996","journal-title":"Br J Pharmacol"},{"key":"R8-20230910","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1523\/JNEUROSCI.14-06-03969.1994","article-title":"Responses of tonically active neurons in the primate\u2019s striatum undergo systematic changes during behavioral sensorimotor conditioning.","volume":"14","author":"Aosaki","year":"1994","journal-title":"J Neurosci"},{"key":"R9-20230910","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"R10-20230910","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm.","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J Neurol Sci"},{"key":"R11-20230910","first-page":"1034","article-title":"Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.","volume":"290","author":"Blanchet","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R12-20230910","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1744-9081-8-12","article-title":"Relevance of animal models to human tardive dyskinesia.","volume":"8","author":"Blanchet","year":"2012","journal-title":"Behav Brain Funct"},{"key":"R13-20230910","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/jpet.111.189100","article-title":"Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.","volume":"340","author":"Bordia","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-20230910","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.expneurol.2016.09.009","article-title":"Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.","volume":"286","author":"Bordia","year":"2016","journal-title":"Exp Neurol"},{"key":"R15-20230910","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.neubiorev.2008.03.012","article-title":"Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.","volume":"32","author":"Buben\u00edkov\u00e1-Valesov\u00e1","year":"2008","journal-title":"Neurosci Biobehav Rev"},{"key":"R16-20230910","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1523\/JNEUROSCI.14-09-05471.1994","article-title":"The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition.","volume":"14","author":"Buller","year":"1994","journal-title":"J Neurosci"},{"key":"R18-20230910","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.brainres.2004.10.038","article-title":"Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.","volume":"1031","author":"Burger","year":"2005","journal-title":"Brain Res"},{"key":"R19-20230910","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1002\/jcp.25843","article-title":"NMDA receptor subunit composition controls dendritogenesis of hippocampal neurons through CAMKII, CREB-P, and H3K27ac.","volume":"232","author":"Bustos","year":"2017","journal-title":"J Cell Physiol"},{"key":"R20-20230910","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis.","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"R21-20230910","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"R22-20230910","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00702-018-1865-5","article-title":"The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.","volume":"125","author":"Carta","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"R23-20230910","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1042\/BST20140006","article-title":"Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson\u2019s disease.","volume":"42","author":"Cenci","year":"2014a","journal-title":"Biochem Soc Trans"},{"key":"R24-20230910","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications.","volume":"5","author":"Cenci","year":"2014b","journal-title":"Front Neurol"},{"key":"R25-20230910","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00702-018-1886-0","article-title":"On the neuronal circuitry mediating L-Dopa induced dyskinesia.","volume":"8","author":"Cenci","year":"2018","journal-title":"J Neural Transm"},{"key":"R26-20230910","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.1523\/JNEUROSCI.1274-04.2004","article-title":"Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors.","volume":"24","author":"Centonze","year":"2004","journal-title":"J Neurosci"},{"key":"R27-20230910","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pnpbp.2012.10.018","article-title":"Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.","volume":"46","author":"Cho","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R28-20230910","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1017\/S1092852916000894","article-title":"Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.","volume":"22","author":"Choi","year":"2017","journal-title":"CNS Spectr"},{"key":"R29-20230910","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.neuron.2013.12.027","article-title":"Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling.","volume":"81","author":"Chuhma","year":"2014","journal-title":"Neuron"},{"key":"R30-20230910","first-page":"1","article-title":"Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication \u2013 what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"71","author":"Citrome","year":"2017","journal-title":"Inter J Clin Pract"},{"key":"R31-20230910","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2018.02.037","article-title":"Clinical management of tardive dyskinesia: five steps to success.","volume":"15","author":"Citrome","year":"2018","journal-title":"J Neurol Sci"},{"key":"R33-20230910","first-page":"769","article-title":"Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.","volume":"249","author":"Coffin","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R34-20230910","first-page":"53","article-title":"Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and mood disorder.","volume":"47","author":"Correll","year":"2017","journal-title":"Psychopharmacol Bull"},{"key":"R35-20230910","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.7901908","article-title":"Oxidative stress, glutamate, and neurodegenerative disorders.","volume":"262","author":"Coyle","year":"1993","journal-title":"Science"},{"key":"R36-20230910","doi-asserted-by":"crossref","first-page":"9574","DOI":"10.1523\/JNEUROSCI.1196-12.2012","article-title":"Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.","volume":"32","author":"Creed","year":"2012","journal-title":"J Neurosci"},{"key":"R37-20230910","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.euroneuro.2010.06.012","article-title":"Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.","volume":"21","author":"Creed","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"R38-20230910","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bbr.2011.01.025","article-title":"Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.","volume":"219","author":"Creed-Carson","year":"2011","journal-title":"Behav Brain Res"},{"key":"R39-20230910","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2018.02.007","article-title":"Tardive dyskinesia: epidemiology.","volume":"389","author":"D\u2019Abreu","year":"2018","journal-title":"J Neurol Sci"},{"key":"R40-20230910","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archpsyc.64.2.170","article-title":"Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.","volume":"64","author":"Damier","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"R41-20230910","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pneurobio.2016.03.004","article-title":"Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications.","volume":"151","author":"De Deurwaerd\u00e8re","year":"2017","journal-title":"Prog Neurobiol"},{"key":"R42-20230910","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00221-013-3508-2","article-title":"Multiple controls exerted by 5HT2C receptors upon basal ganglia function: from physiology to pathophysiology.","volume":"4","author":"De Deurwaerd\u00e8re","year":"2013","journal-title":"Exp Brain Res"},{"key":"R43-20230910","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1523\/JNEUROSCI.20-13-05170.2000","article-title":"Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats.","volume":"20","author":"De Deurwaerd\u00e8re","year":"2000","journal-title":"J Neurosci"},{"key":"R44-20230910","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00213-003-1466-2","article-title":"Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.","volume":"169","author":"De Souza","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R45-20230910","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mds.1112","article-title":"Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study.","volume":"16","author":"Del Dotto","year":"2001","journal-title":"Mov Disord"},{"key":"R46-20230910","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2017.05.010","article-title":"Long-term follow-up of bilateral subthalamic deep brain stimulation for refractory tardive dystonia.","volume":"41","author":"Deng","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"R47-20230910","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.11.009","article-title":"New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.","volume":"157","author":"Di Giovanni","year":"2016","journal-title":"Pharmacol Ther"},{"key":"R48-20230910","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0079-6123(08)00902-3","article-title":"Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.","volume":"172","author":"Di Matteo","year":"2008","journal-title":"Prog Brain Res"},{"key":"R49-20230910","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF02806012","article-title":"Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.","volume":"127","author":"Egan","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R50-20230910","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/BF00441962","article-title":"Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia.","volume":"98","author":"Ellison","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"R51-20230910","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00177570","article-title":"Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats.","volume":"96","author":"Ellison","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"R52-20230910","first-page":"217","article-title":"Prevention and treatment of antipsychotic-induced tardive dyskinesia.","volume":"87","author":"Erbe","year":"2019","journal-title":"Fortschr Neurol Psychiatr"},{"key":"R53-20230910","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of valbenazine in participants with tardive dyskinesia: results of the 1-Year KINECT 3 Extension Study.","volume":"78","author":"Factor","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"R54-20230910","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1471-4159.2008.05439.x","article-title":"Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.","volume":"106","author":"Fantin","year":"2008","journal-title":"J Neurochem"},{"key":"R55-20230910","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R56-20230910","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses.","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr Scand"},{"key":"R57-20230910","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.3390\/biom5043448","article-title":"On the role of glutamate in presynaptic development: possible contributions of presynaptic NMDA receptors.","volume":"5","author":"Fedder","year":"2015","journal-title":"Biomolecules"},{"key":"R58-20230910","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study.","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"R59-20230910","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1038\/ncomms6316","article-title":"Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.","volume":"5","author":"Fieblinger","year":"2014","journal-title":"Nat Commun"},{"key":"R60-20230910","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.","volume":"21","author":"Fox","year":"2006","journal-title":"Mov Disord"},{"key":"R61-20230910","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2018.02.008","article-title":"The nosology of tardive syndromes.","volume":"389","author":"Frei","year":"2018","journal-title":"J Neurol Sci"},{"key":"R62-20230910","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1113\/jphysiol.2014.273755","article-title":"Assembly of AMPA receptors: mechanisms and regulation.","volume":"593","author":"Gan","year":"2015","journal-title":"J Physiol"},{"key":"R63-20230910","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine.","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu Rev Neurosci"},{"key":"R64-20230910","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0091-3057(92)90383-Q","article-title":"Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats.","volume":"41","author":"Gong","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"key":"R65-20230910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12762","article-title":"Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.","volume":"1349","author":"Gonzales","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"R67-20230910","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12031-018-1083-5","article-title":"The neurogenesis actuator and NR2B\/NMDA receptor antagonist Ro25-6981 consistently improves spatial memory retraining via brain region-specific gene expression.","volume":"65","author":"Gruden","year":"2018","journal-title":"J Mol Neurosci"},{"key":"R68-20230910","first-page":"167","article-title":"Neurobiochemical changes in tardive dyskinesia.","volume":"14 Spec No","author":"Gunne","year":"1988","journal-title":"Encephale"},{"key":"R69-20230910","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"key":"R70-20230910","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0006-8993(98)00196-6","article-title":"Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia.","volume":"796","author":"Hamid","year":"1998","journal-title":"Brain Res"},{"key":"R71-20230910","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia.","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"},{"key":"R72-20230910","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1017\/S1092852919000385","article-title":"45 Long-term treatment with deutetrabenazine is associated with continued improvement in tardive dyskinesia: Results from an open-label extension study.","volume":"24","author":"Hauser","year":"2019","journal-title":"CNS Spectr"},{"key":"R73-20230910","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mds.27630","article-title":"Tardive dyskinesia is associated with altered putamen Akt\/GSK-3\u03b2 signaling in nonhuman primates.","volume":"34","author":"Hernandez","year":"2019","journal-title":"Mov Disord"},{"key":"R74-20230910","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00213-005-2203-9","article-title":"Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat.","volume":"179","author":"Higgins","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R76-20230910","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0306-4522(00)00487-5","article-title":"Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens.","volume":"102","author":"Hussain","year":"2001","journal-title":"Neurosci"},{"key":"R77-20230910","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.expneurol.2013.09.003","article-title":"Modulating mGluR5 and 5-HT1A\/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.","volume":"250","author":"Iderberg","year":"2013","journal-title":"Exp Neurol"},{"key":"R78-20230910","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/FBP.0000000000000118","article-title":"Investigating complex basal ganglia circuitry in the regulation of motor behaviour, with particular focus on orofacial movement.","volume":"26","author":"Ikeda","year":"2015","journal-title":"Behav Pharmacol"},{"key":"R79-20230910","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s007020050234","article-title":"Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia.","volume":"106","author":"Ikeda","year":"1999","journal-title":"J Neural Transm (Vienna)"},{"key":"R80-20230910","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1017\/S1461145709990319","article-title":"Differential c-Fos induction by different NMDA receptor antagonists with antidepressant efficacy: potential clinical implications.","volume":"12","author":"Inta","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"R81-20230910","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1176\/ajp.156.2.309","article-title":"Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.","volume":"156","author":"Jeste","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R82-20230910","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.111.187443","article-title":"The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson\u2019s disease.","volume":"340","author":"Jones","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R83-20230910","first-page":"61","article-title":"Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder.","volume":"47","author":"Josiassen","year":"2017","journal-title":"Psychopharmacol Bull"},{"key":"R84-20230910","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R85-20230910","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R86-20230910","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/exnr.1997.6552","article-title":"The effect of chronic haloperidol treatment on dendritic spines in the rat striatum.","volume":"146","author":"Kelley","year":"1997","journal-title":"Exp Neurol"},{"key":"R87-20230910","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00002826-199212000-00006","article-title":"Synaptic plasticity in the rat striatum following chronic haloperidol treatment.","volume":"15","author":"Kerns","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"R88-20230910","doi-asserted-by":"crossref","first-page":"136","DOI":"10.9734\/INDJ\/2014\/7970","article-title":"Dextromethorphan for tardive dyskinesia.","volume":"3","author":"Kim","year":"2014","journal-title":"Inter Neuropsych Disease J"},{"key":"R89-20230910","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.biopsych.2011.10.002","article-title":"Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations.","volume":"71","author":"Kocsis","year":"2012","journal-title":"Biol Psychiatry"},{"key":"R90-20230910","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00213-006-0348-9","article-title":"Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.","volume":"185","author":"Konitsiotis","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R91-20230910","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/7854_2015_395","article-title":"Lifelong rodent model of tardive dyskinesia-persistence after antipsychotic drug withdrawal.","volume":"29","author":"Kostrzewa","year":"2016","journal-title":"Curr Top Behav Neurosci"},{"key":"R92-20230910","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF03033481","article-title":"Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment.","volume":"11","author":"Kostrzewa","year":"2007","journal-title":"Neurotox Res"},{"key":"R93-20230910","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jneumeth.2017.05.007","article-title":"Purposeless oral activity induced by meta-chlorophenylpiperazine (m-CPP): undefined tic-like behaviors?","volume":"292","author":"Kreiss","year":"2017","journal-title":"J Neurosci Methods"},{"key":"R94-20230910","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00221-013-3478-4","article-title":"The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.","volume":"230","author":"Lagi\u00e8re","year":"2013","journal-title":"Exp Brain Res"},{"key":"R95-20230910","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neuroscience.2003.08.019","article-title":"Role of NR2B-containing N-methyl-D-aspartate receptors in haloperidol-induced c-Fos expression in the striatum and nucleus accumbens.","volume":"122","author":"Lee","year":"2003","journal-title":"Neuroscience"},{"key":"R96-20230910","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroscience.2017.07.068","article-title":"Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.","volume":"361","author":"L\u00e9vesque","year":"2017","journal-title":"Neuroscience"},{"key":"R97-20230910","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pnpbp.2013.04.017","article-title":"Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain.","volume":"45","author":"Lima-Ojeda","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R98-20230910","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0304-3940(90)90463-J","article-title":"Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons.","volume":"115","author":"Lindefors","year":"1990","journal-title":"Neurosci Lett"},{"key":"R99-20230910","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0304-3940(87)90057-7","article-title":"Subchronic haloperidol and sulpiride treatment induces region-specific changes in tissue levels of putative amino acid transmitters in rat brain.","volume":"74","author":"Lindefors","year":"1987","journal-title":"Neurosci Lett"},{"key":"R100-20230910","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s00213-014-3582-6","article-title":"Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies.","volume":"231","author":"Lister","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"R101-20230910","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.2015.1050376","article-title":"Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in phase II and phase III clinical trials.","volume":"20","author":"Lockwood","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"R102-20230910","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.expneurol.2004.01.018","article-title":"Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson\u2019s disease.","volume":"187","author":"L\u00f6schmann","year":"2004","journal-title":"Exp Neurol"},{"key":"R103-20230910","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00002826-199212000-00002","article-title":"Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.","volume":"15","author":"Lublin","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"R104-20230910","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuroscience.2004.09.042","article-title":"Glutamate and GABA receptor signalling in the developing brain.","volume":"130","author":"Luj\u00e1n","year":"2005","journal-title":"Neuroscience"},{"key":"R105-20230910","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1021\/cn400016d","article-title":"GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.","volume":"4","author":"Mabrouk","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"R106-20230910","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","article-title":"New targets for rapid antidepressant action.","volume":"152","author":"Machado-Vieira","year":"2017","journal-title":"Prog Neurobiol"},{"key":"R107-20230910","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/mds.25909","article-title":"Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.","volume":"29","author":"Mahmoudi","year":"2014","journal-title":"Mov Disord"},{"key":"R108-20230910","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1460-9568.2002.01944.x","article-title":"Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to \u201cearly onset\u201d vacuous chewing.","volume":"15","author":"Marchese","year":"2002","journal-title":"Eur J Neurosci"},{"key":"R109-20230910","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1073\/pnas.1835724100","article-title":"Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson\u2019s disease treatment.","volume":"100","author":"Marino","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R110-20230910","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1523\/JNEUROSCI.2155-04.2004","article-title":"D2 dopamine receptor-mediated modulation of voltage-dependent Na+ channels reduces autonomous activity in striatal cholinergic interneurons.","volume":"24","author":"Maurice","year":"2004","journal-title":"J Neurosci"},{"key":"R111-20230910","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs.","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu Rev Med"},{"key":"R112-20230910","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs.","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"R113-20230910","first-page":"587","article-title":"Effects of antipsychotic drugs on serotonin receptors.","volume":"43","author":"Meltzer","year":"1991","journal-title":"Pharmacol Rev"},{"key":"R114-20230910","doi-asserted-by":"crossref","first-page":"7798","DOI":"10.1523\/JNEUROSCI.20-20-07798.2000","article-title":"Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias.","volume":"20","author":"Meredith","year":"2000","journal-title":"J Neurosci"},{"key":"R115-20230910","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in dchizophrenia: a meta-analysis of proton magnetic rresonance spectroscopy studies.","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"R116-20230910","first-page":"492","article-title":"Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset.","volume":"6","author":"Mitchell","year":"2006","journal-title":"Behav Pharmacol"},{"key":"R117-20230910","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.256.5060.1217","article-title":"Heteromeric NMDA receptors: molecular and functional distinction of subtypes.","volume":"256","author":"Monyer","year":"1992","journal-title":"Science"},{"key":"R118-20230910","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/syn.20295","article-title":"Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.","volume":"60","author":"Morissette","year":"2006","journal-title":"Synapse"},{"key":"R119-20230910","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1046\/j.1471-4159.1998.70052147.x","article-title":"In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits.","volume":"70","author":"Mutel","year":"1998","journal-title":"J Neurochem"},{"key":"R120-20230910","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00008877-200105000-00006","article-title":"Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.","volume":"12","author":"Naidu","year":"2001a","journal-title":"Behav Pharmacol"},{"key":"R121-20230910","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0014-2999(01)01284-5","article-title":"Effect of 5-HT1A and 5-HT2A\/2C receptor modulation on neuroleptic-induced vacuous chewing movements.","volume":"428","author":"Naidu","year":"2001b","journal-title":"Eur J Pharmacol"},{"key":"R122-20230910","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.expneurol.2004.05.004","article-title":"The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson\u2019s disease.","volume":"188","author":"Nash","year":"2004","journal-title":"Exp Neurol"},{"key":"R123-20230910","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1017\/S1461145712000417","article-title":"Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson\u2019s disease.","volume":"16","author":"Navailles","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"R124-20230910","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.chembiol.2016.08.001","article-title":"Shedding light on metabotropic glutamate receptors.","volume":"23","author":"Nicoletti","year":"2016","journal-title":"Cell Chem Biol"},{"key":"R125-20230910","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1124\/mol.108.049551","article-title":"Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.","volume":"74","author":"Niswender","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R126-20230910","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov Disord"},{"key":"R127-20230910","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mds.26326","article-title":"Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.","volume":"30","author":"Paolone","year":"2015","journal-title":"Mov Disord"},{"key":"R128-20230910","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a rando mized, double-blind, placebo-controlled study.","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"R129-20230910","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002130050993","article-title":"New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.","volume":"144","author":"Peacock","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R130-20230910","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2014.05.004","article-title":"Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.","volume":"144","author":"Quik","year":"2014","journal-title":"Pharmacol Ther"},{"key":"R131-20230910","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1017\/S146114579900156X","article-title":"Three cases of improvement of tardive dyskinesia following olanzapine treatment.","volume":"2","author":"Raja","year":"1999","journal-title":"Int J Neuropsychopharmacol"},{"key":"R132-20230910","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neuropharm.2017.02.003","article-title":"Involvement of GluN2B subunit containing N-methyl-d-aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta (A\u03b2) in murine models of Alzheimer\u2019s disease (AD).","volume":"123","author":"Rammes","year":"2017","journal-title":"Neuropharmacology"},{"key":"R133-20230910","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0706743719828968","article-title":"Treatment recommendations for tardive dyskinesia.","volume":"64","author":"Ricciardi","year":"2019","journal-title":"Can J Psychiatry"},{"key":"R134-20230910","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0306-4522(92)90054-6","article-title":"Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine.","volume":"46","author":"Robertson","year":"1992","journal-title":"Neuroscience"},{"key":"R135-20230910","first-page":"1058","article-title":"Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity.","volume":"271","author":"Robertson","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R136-20230910","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/0024-3205(83)90155-8","article-title":"Induction of oral dyskinesias in naive rats by D1 stimulation.","volume":"33","author":"Rosengarten","year":"1983","journal-title":"Life Sci"},{"key":"R137-20230910","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/0091-3057(93)90140-O","article-title":"A subpopulation of dopamine D1 receptors mediate repetitive jaw movements in rats.","volume":"45","author":"Rosengarten","year":"1993","journal-title":"Pharmacol Biochem Behav"},{"key":"R138-20230910","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00427326","article-title":"Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats.","volume":"85","author":"Rupniak","year":"1985","journal-title":"Psychopharmacol"},{"key":"R139-20230910","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.","volume":"330","author":"Rylander","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"R140-20230910","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol Dis"},{"key":"R141-20230910","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/NEN.0b013e31819cabe4","article-title":"Metabotropic glutamate receptor II in the brains of Parkinsonian patients.","volume":"68","author":"Samadi","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"R142-20230910","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2018.03.003","article-title":"mGlu receptors in the treatment of Parkinson\u2019s disease and L-Dopa-induced dyskinesia.","volume":"38","author":"Sebastianutto","year":"2018","journal-title":"Curr Opinion in Pharmacol"},{"key":"R143-20230910","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/npp.2016.173","article-title":"Haloperidol selectively remodels striatal indirect pathway circuits.","volume":"42","author":"Sebel","year":"2016","journal-title":"Neuropsychopharmacol"},{"key":"R144-20230910","first-page":"1","article-title":"Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system.","volume":"107","author":"Scheel-Kr\u00fcger","year":"1986","journal-title":"Acta Neurol Scand Suppl"},{"key":"R145-20230910","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/978-3-642-70140-5_6","article-title":"New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia.","volume":"2","author":"Scheel-Kr\u00fcger","year":"1985","journal-title":"Psychopharmacology Suppl"},{"key":"R146-20230910","first-page":"165","article-title":"Role of GABA in the striatal output system: globus pallidus, nucleus entopeduncularis, substantia nigra and nucleus subthalamicus.","volume":"30","author":"Scheel-Kr\u00fcger","year":"1981a","journal-title":"Adv Biochem Psychopharmacol"},{"key":"R147-20230910","first-page":"23","article-title":"The role of GABA in the basal ganglia and limbic system for behaviour.","volume":"29","author":"Scheel-Kr\u00fcger","year":"1981b","journal-title":"Adv Biochem Psychopharmacol"},{"key":"R148-20230910","first-page":"550","article-title":"Paroxysmale dyskinesen als megaphenwirkung [paroxysmal dyskinesia as the effect of megaphen].","volume":"28","author":"Sch\u00f4necker","year":"1957","journal-title":"Nervenarzt"},{"key":"R149-20230910","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-2999(94)90722-6","article-title":"Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats.","volume":"263","author":"See","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"R150-20230910","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0014-2999(90)90077-J","article-title":"Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia.","volume":"181","author":"See","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"R151-20230910","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.156.6.876","article-title":"Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.","volume":"156","author":"Seeman","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R152-20230910","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson\u2019s disease.","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog Neurobiol"},{"key":"R153-20230910","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000444278","article-title":"Case reports showing a long-term effect of subanesthetic ketamine infusion in reducing l-DOPA-induced dyskinesias.","volume":"8","author":"Sherman","year":"2016","journal-title":"Case Rep Neurol"},{"key":"R154-20230910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JEP.S63553","article-title":"Experimental treatment of antipsychotic-induced movement disorders.","volume":"8","author":"Shireen","year":"2016","journal-title":"J Exp Pharmacol"},{"key":"R155-20230910","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia.","volume":"389","author":"Solmi","year":"2018","journal-title":"J Neurol Sci"},{"key":"R156-20230910","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0169-328X(98)00293-9","article-title":"Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat.","volume":"64","author":"Standaert","year":"1999","journal-title":"Brain Res Mol Brain Res"},{"key":"R157-20230910","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/exnr.2000.7374","article-title":"Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors.","volume":"163","author":"Steece-Collier","year":"2000","journal-title":"Exper Neurol"},{"key":"R158-20230910","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0014-2999(89)90608-0","article-title":"Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs.","volume":"162","author":"Stewart","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"R159-20230910","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0006-8993(82)90420-6","article-title":"Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum.","volume":"250","author":"Stoof","year":"1982","journal-title":"Brain Res"},{"key":"R160-20230910","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/(SICI)1098-2396(199611)24:3<256::AID-SYN8>3.0.CO;2-D","article-title":"Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat.","volume":"24","author":"Stoessl","year":"1996","journal-title":"Synapse"},{"key":"R161-20230910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cophys.2017.12.004","article-title":"Triheteromeric NMDA receptors: from structure to synaptic physiology.","volume":"2","author":"Stroebel","year":"2018","journal-title":"Curr Opin Physiol"},{"key":"R162-20230910","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pneurobio.2018.07.003","article-title":"Selective basal ganglia vulnerability to energy deprivation: experimental and clinical evidences.","volume":"169","author":"Tambasco","year":"2018","journal-title":"Prog Neurobiol"},{"key":"R163-20230910","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1152\/jn.90486.2008","article-title":"A dopamine-acetylcholine cascade: simulating learned and lesion-induced behavior of striatal cholinergic interneurons.","volume":"100","author":"Tan","year":"2008","journal-title":"J Neurophysiol"},{"key":"R164-20230910","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12031-007-0034-3","article-title":"Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors.","volume":"32","author":"Tarazi","year":"2007","journal-title":"J Mol Neurosci"},{"key":"R165-20230910","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1124\/jpet.103.052597","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment.","volume":"306","author":"Tarazi","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R166-20230910","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s002130050147","article-title":"Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics.","volume":"128","author":"Tarazi","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R167-20230910","first-page":"149","article-title":"Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons.","volume":"11","author":"Threlfell","year":"2011","journal-title":"Front Syst Neurosci"},{"key":"R168-20230910","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/ajp.155.9.1207","article-title":"Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.","volume":"155","author":"Tsai","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R169-20230910","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","article-title":"The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.","volume":"165","author":"Turrone","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R170-20230910","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00441188","article-title":"Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy.","volume":"1","author":"Uhrbrand","year":"1960","journal-title":"Psychopharmacol"},{"key":"R171-20230910","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-3-319-45096-4_12","article-title":"Astroglia, glutamatergic transmission and psychiatric diseases.","volume":"13","author":"Verkhratsky","year":"2016","journal-title":"Adv Neurobiol"},{"key":"R172-20230910","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0074-7742(08)60282-2","article-title":"Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms.","volume":"31","author":"Waddington","year":"1989","journal-title":"Int Rev Neurobiol"},{"key":"R173-20230910","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF02244220","article-title":"Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.","volume":"101","author":"Waddington","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"R174-20230910","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.6132447","article-title":"Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.","volume":"220","author":"Waddington","year":"1983","journal-title":"Science"},{"key":"R175-20230910","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1126\/science.417399","article-title":"Dyskinesias evoked in monkeys by weekly administration of haloperidol.","volume":"200","author":"Weiss","year":"1978","journal-title":"Science"},{"key":"R176-20230910","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00492366","article-title":"Movement disorders induced in monkeys by chronic haloperidol treatment.","volume":"53","author":"Weiss","year":"1977","journal-title":"Psychopharmacology (Berl)"},{"key":"R177-20230910","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neuropharm.2004.03.011","article-title":"NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.","volume":"47","author":"Wessell","year":"2004","journal-title":"Neuropharmacology"},{"key":"R178-20230910","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2013.01.001","article-title":"Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis.","volume":"74","author":"Wiescholleck","year":"2013","journal-title":"Neuropharmacology"},{"key":"R179-20230910","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jns.2018.02.011","article-title":"Genetics of tardive dyskinesia: promising leads and ways forward.","volume":"389","author":"Zai","year":"2018","journal-title":"J Neurol Sci"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:12:59Z","timestamp":1694333579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":175,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000563","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,25]]}}}